

## Multiple Sclerosis

### REFERENCES

- Agnello E, Palmo A. The efficacy of dietetic intervention in multiple sclerosis. *Minerva Gastroenterol Dietol* . 2004 Dec;50(4):317-23.
- Agranoff BWA, Goldberg D. Diet and the geographical distribution of multiple sclerosis. *Lancet*. 1974 Nov 2;2(7888):1061-6.
- Alotaibi S, Kennedy J, et al. Epstein-Barr virus in pediatric multiple sclerosis. *JAMA*. 2004 Apr 21;291(15):1875-9.
- Arfsten D, Johnson E, et al. Impact of 30-day oral dosing with N-acetyl-L-cysteine on Sprague-Dawley rat physiology. *Int J Toxicol*. 2004 Jul-Aug;23(4):239-47.
- Bannenberg GL, Chiang N, Molecular circuits of resolution: formation and actions of resolvins and protectins. *J Immunol*. 2005 Apr 1;174(7):4345-55.
- Bansil S, Lee HJ, et al. Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. *Acta Neurol Scand*. 1999 Feb;99(2):91-4.
- Bates D. Dietary lipids and multiple sclerosis. *Ups J Med Sci Suppl* . 1990;48:173-87.
- Bates MN, Fawcett J, et al. Health effects of dental amalgam exposure: a retrospective cohort study. *Int J Epidemiol*. 2004 Aug;33(4):894-902. Epub 2004 May 20.
- Biernacki K, Prat A, et al. Regulation of cellular and molecular trafficking across human brain endothelial cells by Th1- and Th2-polarized lymphocytes. *J Neuropathol Exp Neurol*. 2004 Mar;63(3):223-32.
- Bonakdar RA, Guarneri E, et al. Coenzyme Q10. *Am Fam Physician* . 2005 Sep 15;72(6):1065-70.
- Butcher J. The distribution of multiple sclerosis in relation to the dairy industry and milk consumption. *N Z Med J*. 1976 Jun 23;83(566):427-30.
- Calabrese VP, Isaacs ER, et al. Dehydroepiandrosterone in multiple sclerosis: positive effects on the fatigue syndrome in a non-randomized study. In: Kalimi M, Regelson W, eds. *The Biological Role of Dehydroepiandrosterone (DHEA)*. New York, NY : Walter de Gruyter; 1990:95-100.
- Cantorna MT, Hayes CE, et al. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. *Proc Natl Acad Sci U S A* . 1996 Jul 23;93(15):7861-4.
- Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? *Proc Soc Exp Biol Med*. 2000 Mar;223(3):230-3.
- Chaudhuri A. Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. *Med Hypotheses* . 2005;64(3):608-18.
- Chofflon M. Mechanisms of action for treatments in multiple sclerosis: does a heterogeneous disease demand a multi-targeted therapeutic approach? *BioDrugs* . 2005;19(5):299-308.
- Cournu-Rebeix I, Genin E, et al. Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis. *Genes Immun*. 2003 Oct;4(7):518-23.
- de Bustos F, Jimenez-Jimenez FJ, et al. Serum levels of coenzyme Q10 in patients with multiple sclerosis. *Acta Neurol Scand* . 2000 Mar;101(3):209-11.

Dedrick RL, Bodary S, et al. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. *Expert Opin Biol Ther.* 2003 Feb;3(1):85-95.

Drew PD, Chavis JA. Female sex steroids: effects upon microglial cell activation. *J Neuroimmunol.* 2000 Nov 1;111(1-2):77-85.

Du C, Khalil MW, et al. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. *J Immunol.* 2001 Dec 15;167(12):7094-101.

Dworkin RH, Bates D, et al. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. *Neurology.* 1984 Nov;34(11):1441-5.

El-Etr M, Vukusic S, et al. Steroid hormones in multiple sclerosis. *J Neurol Sci.* 2005 Jun 15;233(1-2):49-54. Review.

Farrell R, Heaney D, et al. Emerging therapies in multiple sclerosis. *Expert Opin Emerg Drugs.* 2005 Nov;10(4):797-816.

Feng J, Misu T, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. *Mult Scler.* 2004 Oct;10(5):494-8.

Ferrucci L, Cherubini A, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. *J Clin Endocrinol Metab.* 2005 Oct 18; [Epub ahead of print]

Garcion E, Sindji L, et al. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. *Acta Neuropathol (Berl).* 2003 May;105(5):438-48. Epub 2003 Jan 31.

Gilgun-Sherki Y, Barhum Y, et al. Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant. *J Mol Neurosci.* 2005;27(1):125-35.

Guggenmos J, Schubart AS, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. *J Immunol.* 2004 Jan 1;172(1):661-8.

Haahr S, Munch M. The association between multiple sclerosis and infection with Epstein-Barr virus and retrovirus. *J Neurovirol.* 2000 May;6(suppl 2):S76-9. Review.

Hanley DA, Davison KS. Vitamin D insufficiency in North America. *J Nutr.* 2005 Feb;135(2):332-7.

Harbige LS, Fisher BA. Dietary fatty acid modulation of mucosally induced tolerogenic immune responses. *Proc Nutr Soc.* 2001 Nov;60(4):449-56.

Harbige LS, Layward L, et al. The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production. *Clin Exp Immunol.* 2000 Dec;122(3):445-52.

Hartung HP, Bar-Or A, et al. What do we know about the mechanism of action of disease-modifying treatments in MS? *J Neurol.* 2004 Sep;251(suppl 5):v12-v29.

Henke AF, Cohle SD, et al. Fatal hyperthermia secondary to sunbathing in a patient with multiple sclerosis. *Am J Forensic Med Pathol.* 2000 Sep;21(3):204-6.

Hoffman GE, Le WW, et al. Divergent effects of ovarian steroids on neuronal survival during experimental allergic encephalitis in Lewis rats. *Exp Neurol.* 2001 Oct;171(2):272-84.

Holick MF. The vitamin D epidemic and its health consequences. *J Nutr.* 2005 Nov;135(11):2739S-48S.

Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. *J Nutr.* 2005 Feb;135(2):317-22.

Homa ST, Conroy DM, et al. Fatty acid patterns of red blood cell phospholipids in patients with multiple sclerosis. *Lancet.* 1981 Aug 29;2(8244):474.

Horrobin DF. Essential fatty acid metabolism and its modification in atopic eczema. *Am J Clin Nutr.* 2000 Jan;71(suppl 1):367S-

Horrobin DF. Essential fatty acids in the management of impaired nerve function in diabetes. *Diabetes*. 1997 Sep;46(suppl 2):S90-3.

Hughes MD. Multiple sclerosis and pregnancy. *Neurol Clin*. 2004 Nov;22(4):757-69. Review.

Jamal GA. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. *Diabet Med*. 1994 Mar;11(2):145-9.

Kidd PM. Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. *Altern Med Rev*. 2001 Dec;6(6):540-66.

Kim S, Liva SM, et al. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. *Neurology*. 1999 Apr 12;52(6):1230-8.

Kohlmeier RE, DiMaio VJ, et al. Fatal hyperthermia in hot baths in individuals with multiple sclerosis. *Am J Forensic Med Pathol*. 2000 Sep;21(3):201-3.

Kumpfel T, Then Bergh F, et al. Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. *Neuroendocrinology*. 1999 Dec;70(6):431-8.

Landtblom AM, Flodin U, et al. Organic solvents and multiple sclerosis: a synthesis of the current evidence. *Epidemiology*. 1996 Jul;7(4):429-33.

Lauer K. Diet and multiple sclerosis. *Neurology* 1997;49:S55-S61.

Lauer K, Firnhaber W. An evaluation of laboratory investigations in patients with multiple sclerosis. *J Chronic Dis*. 1986;39(10):767-74.

Lieb K, Engels S, et al. Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. *Neurochem Int*. 2003 Jan;42(2):131-7.

Mai J, Sorensen PS, et al. High-dose antioxidant supplementation to MS patients: effects on glutathione peroxidase, clinical safety, and absorption of selenium. *Biol Trace Elem Res*. 1990 Feb;24(2):109-17.

Malosse D, Perron H. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. *Neuroepidemiology*. 1992;11(4-6):304-12.

Marracci GH, Jones RE, et al. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. *J Neuroimmunol*. 2002 Oct;131(1-2):104-14.

Marracci GH, McKeon GP, et al. Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. *J Neurosci Res*. 2004 Nov 1;78(3):362-70.

Mazzella GL, Sinforiani E, et al. Blood cells glutathione peroxidase activity and selenium in multiple sclerosis. *Eur Neurol*. 1983;22(6):442-6.

Merlino LA, Curtis J, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. *Arthritis Rheum*. 2004 Jan;50(1):72-7.

Miller A, Korem M, et al. Vitamin B12, demyelination, remyelination and repair in multiple sclerosis. *J Neurol Sci*. 2005 Jun 15;233(1-2):93-7.

Miller DH, Khan OA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. 2003 Jan 2;348(1):15-23.

Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength-preserving hormone. *Mol Aspects Med*. 2005 Jun;26(3):203-19.

Morini M, Roccatagliata L, et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. *J Neuroimmunol* . 2004 Mar;148(1-2):146-53.

Munch M, Hvas J, et al. The implications of Epstein-Barr virus in multiple sclerosis: a review. *Acta Neurol Scand Suppl* . 1997;169:59-64.

Munger KL, Zhang SM, et al. Vitamin D intake and incidence of multiple sclerosis. *Neurology* . 2004 Jan 13;62(1):60-5.

Murdoch D, Lyseng-Williamson KA. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis. *BioDrugs* . 2005;19(5):323-5.

Mutter J, Naumann J, et al. Amalgam risk assessment with coverage of references up to 2005. *Gesundheitswesen* . 2005 Mar;67(3):204-16.

Noonan CW, Kathman SJ, et al. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. *Neurology*. 2002 Jan 8;58(1):136-8.

Nordvik I, Myhr KM, et al. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. *Acta Neurol Scand*. 2000 Sep;102(3):143-9.

Noseworthy JH. Multiple sclerosis clinical trials: old and new challenges. *Semin Neurol*. 1998;18(3):377-88. Review.

Offner H, Zamora A, et al. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. *J Neuroimmunol* . 2002 Sep;130(1-2):128-39.

Patten SB, Metz LM. Depression in multiple sclerosis. *Psychother Psychosom* . 1997;66(6):286-92. Review.

Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. *Lancet Neurol* . 2003 Sep;2(9):563-6.

Ponsonby AL, Lucas RM, et al. A potential role for UVR and vitamin D in the induction of multiple sclerosis, type 1 diabetes, rheumatoid arthritis. *Photochem Photobiol* . 2005a Feb 1; [Epub ahead of print]

Ponsonby AL, Lucas RM, et al. UVR, vitamin D and three autoimmune diseases: multiple sclerosis, type 1 diabetes, rheumatoid arthritis. *Photochem Photobiol*. 2005b Nov-Dec;81(6):1267-75.

Ponsonby AL, McMichael A, et al. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. *Toxicology* . 2002 Dec 27;181-182:71-8.

Pozzilli C, Falaschi P, et al. MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns. *Neurology* . 1999 Aug 11;53(3):622-4.

Prieto JM, Dapena D, et al. Pentoxifylline: is it useful in multiple sclerosis? *Rev Neurol*. 2001 Mar 16-31;32(6):529-31.

Prochazkova J, Sterzl I, et al. The beneficial effect of amalgam replacement on health in patients with autoimmunity. *Neuro Endocrinol Lett*. 2004 Jun;25(3):211-8.

Ramsaransing GS, Heersema DJ, et al. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. *Eur J Neurol* . 2005 Jul;12(7):514-8.

Reynolds EH. Multiple sclerosis and vitamin B12 metabolism. *J Neuroimmunol* . 1992 Oct;40(2-3):225-30.

Riise T, Moen BE, et al. Organic solvents and the risk of multiple sclerosis. *Epidemiology*. 2002 Nov;13(6):718-20.

Schwarz S, Leweling H. Multiple sclerosis and nutrition. *Mult Scler* . 2005 Feb;11(1):24-32.

Serhan CN. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. *Histochem Cell Biol*. 2004 Oct;122(4):305-21. Epub 2004 Aug 21.

Serhan CN. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. *Curr Opin Clin Nutr Metab Care* . 2005a Mar;8(2):115-21.

- Serhan CN. Novel omega-3-derived local mediators in anti-inflammation and resolution. *Pharmacol Ther* . 2005b Jan;105(1):7-21.
- Shapiro H. Could n-3 polyunsaturated fatty acids reduce pathological pain by direct actions on the nervous system? *Prostaglandins Leukot Essent Fatty Acids*. 2003 Mar;68(3):219-24.
- Siblerud RL, Kienholz E. Evidence that mercury from silver dental fillings may be an etiological factor in multiple sclerosis. *Sci Total Environ*. 1994 Mar 15;142(3):191-205.
- Siemieniuk E, Skrzydlewska E. Coenzyme Q10: its biosynthesis and biological significance in animal organisms and in humans. *Postepy Hig Med Dosw (Online)*. 2005 Apr 18;59:150-9.
- Singh I, Pahan K. Cytokine-mediated induction of ceramide production is redox-sensitive: implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases . *J Biol Chem*. 1998 Aug 7;273(32):20354-62.
- Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. *Philos Trans R Soc Lond B Biol Sci* . 1999 Oct 29;354(1390):1649-73. Review.
- Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. *Eur J Neurol* . 2002 Nov;9(6):557-63.
- Stefflerl A, Schubart A, et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. *J Immunol*. 2000 Sep 1;165(5):2859-65.
- Steiner I, Nisipianu P, et al. Infection and the etiology and pathogenesis of multiple sclerosis. *Curr Neurol Neurosci Rep* . 2001 May;1(3):271-6. Review.
- Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. *Lancet*. 1990 Jul 7;336(8706):37-9.
- Swank RL. Multiple sclerosis: fat-oil relationship. *Nutrition* . 1991 Sep-Oct;7(5):368-76.
- Syburra C, Passi S. Oxidative stress in patients with multiple sclerosis. *Ukr Biokhim Zh* . 1999 May-Jun;71(3):112-5.
- Trenova AG, Manova MM, et al. Female sex hormones and multiple sclerosis. *Folia Med ( Plovdiv )*. 2004;46(4):11-5. Review.
- van Meeteren ME, Teunissen CE, et al. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. *Eur J Clin Nutr* . 2005 Dec;59(12):1347-61.
- Vollmer TL, Phillips JT, et al. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. *Mult Scler*. 2004 Oct;10(5):511-20.
- Wade DT, Young CA, et al. A randomised placebo-controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2002 Sep;73(3):246-9.
- Weinshenker BG. The natural history of multiple sclerosis. *Neurol Clin*. 1995 Feb;13(1):119-46.
- Weinstock-Guttman B, Baier M, et al. Low-fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. *Prostaglandins Leukot Essent Fatty Acids* . 2005 Nov;73(5):397-404.
- Willer CJ, Dyment DA, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. *Proc Natl Acad Sci U S A* . 2003 Oct 28;100(22):12877-82. Epub 2003 Oct 20.
- Willer CJ, Ebers GC. Susceptibility to multiple sclerosis: interplay between genes and environment. *Curr Opin Neurol*. 2000 Jun;13(3):241-7.
- Wingerchuk DM, Lesaux J, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. *J Neurol Neurosurg Psychiatry* . 2005 Sep;76(9):1294-6.
- Wright JV. Multiple sclerosis. *Nutrition & Healing* 1997;4:1-12.

Yadav V, Marracci G, et al. Lipoic acid in multiple sclerosis: a pilot study. *Mult Scler*. 2005 Apr;11(2):159-65.

Zhang SM, Willett WC, et al. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. *Am J Epidemiol*. 2000 Dec 1;152(11):1056-64.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

**LifeExtension®**

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.